AcuCort Valuation
Is NV5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NV5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NV5's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NV5's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NV5?
Key metric: As NV5 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NV5's PS Ratio? | |
|---|---|
| PS Ratio | 14.3x |
| Sales | SEK 6.99m |
| Market Cap | SEK 99.86m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.6x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NV5's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.4x | ||
B8FK Biofrontera | 0.8x | n/a | €16.4m |
SBX SynBiotic | 7.2x | 39.7% | €27.9m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
HIGH Cantourage Group | 28.4x | 38.6% | €55.6m |
NV5 AcuCort | 14.3x | n/a | €99.9m |
Price-To-Sales vs Peers: NV5 is expensive based on its Price-To-Sales Ratio (14.3x) compared to the peer average (12.4x).
Price to Sales Ratio vs Industry
How does NV5's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 23 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: NV5 is expensive based on its Price-To-Sales Ratio (14.3x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is NV5's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 14.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NV5's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Fortrea Holdings
US$1.8b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.40
7D
-1.6%
1Y
-38.3%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.29
7D
-1.8%
1Y
0.2%